Advertisement: Kao Data Centre mid banner
ARM Innovation Hub
Advertisement: SATAVIA mid banner
Advertisement: partnersand mid banner
Advertisement: RSM mid banner
Advertisement: S-Tech mid banner 3
Advertisement: EBCam mid banner
Advertisement: Cambridge Network mid banner
Mid banner advertisement: BDO
Advertisement: TTP
Advertisement: Bar Ellison mid banner property
Advertisement: Mogrify mid banner
Cambridgeand mid banner advertisement
Barr Ellison Solicitors – commercial property
Advertisement: CJBS mid banner
Advertisement: Simpsons Creative
Advertisement: Excalibur Healthcare mid banner
Advertisement: HCR Hewitsons mid banner
Advertisement: Wild Knight Vodka
31 August, 2017 - 10:27 By Tony Quested

Novacyt targets AIM listing, acquisitions and US expansion

novacyt, infectious diseases, cancer, cambridge

Clinical diagnostics specialist Novacyt, based in Cambridge and Paris, is reaping a handsome return on investment in the business, CEO Graham Mullis has revealed along with the company’s unaudited results for the six months ended June 30.

Quoted in France, the company plans an AIM listing in the UK this year, although no specific timetable has been disclosed. It is also seeking a distributor in the US to underpin further geographical expansion and Mullis said the board is eyeing potential acquisitional opportunities to stretch its global reach.

Mullis said Novacyt continues to deliver robust revenue growth and is moving closer to profitability as the investment programme across the business begins to bear fruit. This is reflected in a 53 per cent increase in revenue at constant exchange rates during the first half of the year, compared to the prior period.

Over the past three years every €1 invested in commercial infrastructure has delivered around €5 of additional sales, which supports the ongoing investment programme.

Novacyt has seen the full benefit of the acquisition of Primerdesign, which is now fully integrated, as well as delivering strong organic sales growth from NOVAprep® and Lab21 in Cambridge, leading to the group delivering significant improvement in EBITDA and reinforcing its accelerated trajectory towards profitability.

Consolidated group sales topped €7 million in the first half compared to €4.95m last time. The EBITDA loss significantly narrowed from €1.6m in 2016 to €0.5m in 2017 as a result of higher sales, improving gross margin and cost controls.


Newsletter Subscription

Stay informed of the latest news and features